Jun 11, 2008 by Brian Orelli, PhDAmylin's Down and Up on DiabetesSo exactly why did it drop and then come back up?
Jun 11, 2008 by Brian Orelli, PhDMylan Takes Generic Aim at TevaMylan licenses a generic version of Teva's MS drug, Copaxone.
Jun 10, 2008 by Brian Orelli, PhDThird Wave's Invader Gets InvadedHologic picks up a promising technology as the diagnostic-testing market picks up steam.
Jun 9, 2008 by Brian Orelli, PhDTreading on a Johnson & Johnson ProductA drug for foot ulcers gets a warning label.
Jun 6, 2008 by Brian Orelli, PhDNatus Hears the Call of ExpansionIs the newfound money burning a hole in the company's coffers?
Jun 5, 2008 by Brian Orelli, PhDDon't Get Your Drug Approved in Europe FirstThe FDA dings Indevus because of European safety issues.
Jun 5, 2008 by Brian Orelli, PhDTest Results Boost Sequenom's StockThey are early results, but the Down syndrome tests could bring big changes to the industry.
Jun 4, 2008 by Brian Orelli, PhDExpanding Possibilities Fail to Expand Rigel's Stock PriceRigel gets positive data on a second indication for its lead drug.
Jun 3, 2008 by Brian Orelli, PhDTaking a Walk With a 10-BaggerAcorda gets it done with phase 3 trial data on a new MS drug.
Jun 2, 2008 by Brian Orelli, PhDValuing One-Drug WondersWith only one drug on the market, these pharmas lack positive earnings.
Jun 2, 2008 by Brian Orelli, PhDThe Anticoagulation Competition BloodbathBayer and Johnson & Johnson give Sanofi's Lovenox another beating.
May 30, 2008 by Brian Orelli, PhDNo Love for Antibiotics From the FDAWyeth gets an approvable letter for its antibiotic Tygacil.
May 29, 2008 by Brian Orelli, PhDMedtronic Sticks It to Boston ScientificMedtronic wins the medical-device patent duel.
May 28, 2008 by Brian Orelli, PhDA Rough Quarter for Generic-Drug MakersInvestors rocked the smaller companies the most.
May 27, 2008 by Brian Orelli, PhDLivin' la VIVUS LocaIrrational exuberance for VIVUS' lead drug candidate?
May 27, 2008 by Brian Orelli, PhDSuper Seed SwapTrading traits seems to be very common these days. The latest deal is between Monsanto and Syngenta.
